Sanofi (SNY) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown
SNY's revenue distribution by segment and geography
By Geography
SNY Revenue Analysis (2014–2025)
As of February 28, 2026, Sanofi (SNY) generated trailing twelve-month (TTM) revenue of $46.72 billion, reflecting explosive growth of +59.9% year-over-year. The most recent quarter (Q4 2025) recorded $12.21 billion in revenue, down 7.3% sequentially.
Looking at the longer-term picture, SNY's 5-year compound annual growth rate (CAGR) stands at +4.6%, indicating moderate growth over time. The company achieved its highest annual revenue of $46.72 billion in 2025, representing a new all-time high.
When compared to Healthcare sector peers including MRK (+1.3% YoY), PFE (-1.6% YoY), and GSK (+1.8% YoY), SNY has outperformed the peer group in terms of revenue growth. Compare SNY vs MRK →
Peer Comparison
Compare SNY's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SNYCurrent | $46.7B | +59.9% | +4.6% | 13.6% | |
| MRK | $65.0B | +1.3% | +9.4% | 41.2% | |
| PFE | $62.6B | -1.6% | +8.5% | 24.7% | |
| GSK | $32.0B | +1.8% | +5.6% | 21.9% | |
| GRFS | $7.2B | +7.3% | +7.2% | 16.5% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $46.72B | +5.5% | $33.79B | 72.3% | $6.34B | 13.6% |
| 2024 | $44.29B | +6.4% | $31.08B | 70.2% | $7.25B | 16.4% |
| 2023 | $41.62B | +2.6% | $28.99B | 69.7% | $6.96B | 16.7% |
| 2022 | $40.56B | +3.5% | $28.68B | 70.7% | $10.16B | 25.1% |
| 2021 | $39.17B | +4.8% | $26.92B | 68.7% | $8.13B | 20.7% |
| 2020 | $37.37B | -0.7% | $25.21B | 67.5% | $14.11B | 37.8% |
| 2019 | $37.63B | +5.5% | $25.65B | 68.2% | $3.05B | 8.1% |
| 2018 | $35.68B | -1.5% | $24.24B | 67.9% | $4.68B | 13.1% |
| 2017 | $36.22B | +4.4% | $24.61B | 67.9% | $5.80B | 16.0% |
| 2016 | $34.70B | -0.5% | $24.00B | 69.2% | $6.53B | 18.8% |
See SNY's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNY Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SNY vs AGIO
See how SNY stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SNY's revenue growth accelerating or slowing?
SNY revenue is accelerating at +59.9% year-over-year, exceeding the 5-year CAGR of +4.6%. TTM revenue reached $46.7B. Growth momentum has increased versus prior periods.
What is SNY's long-term revenue growth rate?
Sanofi's 5-year revenue CAGR of +4.6% reflects the sustained expansion pattern. Current YoY growth of +59.9% is above this long-term average.
How is SNY's revenue distributed by segment?
SNY reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.